Lumida
/ARDT
⌘K
Ardent Health Inc

Ardent Health Inc

ARDT
$10.98USD↑+0.73%+0.08 today

MARKET CAP

1.5B

P/E (TTM)

11.6x

FWD P/E

—

DAY RANGE

$11 – $11

52W RANGE

$8
$15

AI Summary

Stalk
StalkMedium

ARDT broke above its June consolidation but has since drifted sideways near its short-term EMAs without decisive follow-through. The 9, 20, and 50 EMAs are flat to slightly rising, holding price support, while RSI and Options Score remain neutral, signaling no exhaustion. Medium-term bias stays bullish within a Stage 3 regime, but timing is unfavorable until renewed momentum emerges. A pullback to the 10.8–10.9 EMA zone offers a more defined engagement area. The long-term 200-day SMA is still declining, underscoring structural risk.

  • ↑Operating cash flow surged 68% YoY to $197M in Q2 2026.
  • ↑Repurchased $13M of stock in Q2 with $34M authorization remaining.
  • ↓Q2 surgeries declined 2.9%, highlighting demand volatility.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Ardent Health (NYSE: ARDT) is a healthcare organization operating a network of 30 hospitals and over 280 care sites, primarily positioned in fast-growing markets. The company focuses on delivering high-quality and efficient healthcare services through strategic partnerships and continual operational optimization. Ardent Health is currently enhancing its service lines and introducing technological innovations, such as the recent rollout of HelloCare AI, to improve patient care and operational performance in an evolving healthcare landscape.

Bull says

  • ↑Operating cash flow surged 68% YoY to $197M in Q2 2026.
  • ↑Repurchased $13M of stock in Q2 with $34M authorization remaining.
  • ↑Raised IMPACT program savings target above $70M to improve margins.
  • ↑New payer contract expected to add $5–10M to adjusted EBITDA.
  • ↑Surgical volumes rebounded in June–July after spring declines.
  • ↑Attractive valuation supported by high earnings yield and strong leverage.

Bear says

  • ↓Q2 surgeries declined 2.9%, highlighting demand volatility.
  • ↓Revenue guidance skewed to bottom of $6.4–6.7B range.
  • ↓Weak profitability factors signal margin erosion risks.
  • ↓Execution risk elevated if $70M cost savings miss targets.
  • ↓Limited analyst revisions and low institutional ownership weigh on sentiment.
  • ↓No dividend yield deters income-focused investors.

Earnings Call · Q3 2024 · Mgmt. Guidance

Updated 11-15-2025bullish

Transcript signals

Bull points

  • we remain confident in our strategies and the strength of our business. Our company successfully navigated and demonstrated a strong track record of growth during the prior Trump administration, and we have confidence that we are even better prepared and will continue to grow through his next administration.
  • Collectively, we believe that demand for healthcare services will remain strong and Arden is well positioned to continue to drive value to our patients and our shareholders.
  • Growth across our key volume metrics of admissions, inpatient surgeries, and outpatient surgeries modestly accelerated compared to the first half of 2024. Admissions increased 6.4% in the third quarter compared to the prior year, outpacing the 5.3% growth in the first half of 2024.

Bear points

  • Salaries and benefits as a percentage of total revenue increased 60 basis points year over year to 43.8%. This increase is attributable to an additional $8 million of equity-based compensation recorded in the third quarter of 2024 following our IPO in July.
  • Net income guidance has been reduced to reflect an expected delay in receiving business insurance proceeds related to the 2023 cybersecurity event.
Read full transcript analysis ›